Figure 5. AR12 and the drug combination reduce the expression of mutant forms of TAU and APP. HCN2 and BV2 cells were transfected with plasmids to express wild type TAU or TAU 301L. After 24h, cells were treated with vehicle control, AR12 (2 μM), neratinib (50 nM) or the drugs in combination for 6h. Cells were fixed in place and immunostaining performed to determine the expression of TAU, TAU 301L and ERK2. (n = 3 +/-SD) * p < 0.05 less than vehicle control; ** p < 0.05 less than AR12 value. In parallel, HCN2 and BV2 cells were transfected with plasmids to express wild type APP or APP 715 or APP 692. After 24h, cells were treated with vehicle control, AR12 (2 μM), neratinib (50 nM) or the drugs in combination for 6h. Cells were fixed in place and immunostaining performed to determine the expression of APP, APP 715, APP 692 and ERK2. (n = 3 +/-SD) * p < 0.05 less than vehicle control; ** p < 0.05 less than AR12 value.